Cargando…
A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug–food interactions (DFIs) and is well known for its strong drug–drug interaction (DDI) potential. Some of ketoconazole’s potent inhibitory activity can be attributed to its me...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965990/ https://www.ncbi.nlm.nih.gov/pubmed/36840001 http://dx.doi.org/10.3390/pharmaceutics15020679 |
_version_ | 1784896904510832640 |
---|---|
author | Marok, Fatima Zahra Wojtyniak, Jan-Georg Fuhr, Laura Maria Selzer, Dominik Schwab, Matthias Weiss, Johanna Haefeli, Walter Emil Lehr, Thorsten |
author_facet | Marok, Fatima Zahra Wojtyniak, Jan-Georg Fuhr, Laura Maria Selzer, Dominik Schwab, Matthias Weiss, Johanna Haefeli, Walter Emil Lehr, Thorsten |
author_sort | Marok, Fatima Zahra |
collection | PubMed |
description | The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug–food interactions (DFIs) and is well known for its strong drug–drug interaction (DDI) potential. Some of ketoconazole’s potent inhibitory activity can be attributed to its metabolites that predominantly accumulate in the liver. This work aimed to develop a whole-body physiologically based pharmacokinetic (PBPK) model of ketoconazole and its metabolites for fasted and fed states and to investigate the impact of ketoconazole’s metabolites on its DDI potential. The parent–metabolites model was developed with PK-Sim(®) and MoBi(®) using 53 plasma concentration-time profiles. With 7 out of 7 (7/7) DFI AUC(last) and DFI C(max) ratios within two-fold of observed ratios, the developed model demonstrated good predictive performance under fasted and fed conditions. DDI scenarios that included either the parent alone or with its metabolites were simulated and evaluated for the victim drugs alfentanil, alprazolam, midazolam, triazolam, and digoxin. DDI scenarios that included all metabolites as reversible inhibitors of CYP3A4 and P-gp performed best: 26/27 of DDI AUC(last) and 21/21 DDI C(max) ratios were within two-fold of observed ratios, while DDI models that simulated only ketoconazole as the perpetrator underperformed: 12/27 DDI AUC(last) and 18/21 DDI C(max) ratios were within the success limits. |
format | Online Article Text |
id | pubmed-9965990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99659902023-02-26 A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators Marok, Fatima Zahra Wojtyniak, Jan-Georg Fuhr, Laura Maria Selzer, Dominik Schwab, Matthias Weiss, Johanna Haefeli, Walter Emil Lehr, Thorsten Pharmaceutics Article The antifungal ketoconazole, which is mainly used for dermal infections and treatment of Cushing’s syndrome, is prone to drug–food interactions (DFIs) and is well known for its strong drug–drug interaction (DDI) potential. Some of ketoconazole’s potent inhibitory activity can be attributed to its metabolites that predominantly accumulate in the liver. This work aimed to develop a whole-body physiologically based pharmacokinetic (PBPK) model of ketoconazole and its metabolites for fasted and fed states and to investigate the impact of ketoconazole’s metabolites on its DDI potential. The parent–metabolites model was developed with PK-Sim(®) and MoBi(®) using 53 plasma concentration-time profiles. With 7 out of 7 (7/7) DFI AUC(last) and DFI C(max) ratios within two-fold of observed ratios, the developed model demonstrated good predictive performance under fasted and fed conditions. DDI scenarios that included either the parent alone or with its metabolites were simulated and evaluated for the victim drugs alfentanil, alprazolam, midazolam, triazolam, and digoxin. DDI scenarios that included all metabolites as reversible inhibitors of CYP3A4 and P-gp performed best: 26/27 of DDI AUC(last) and 21/21 DDI C(max) ratios were within two-fold of observed ratios, while DDI models that simulated only ketoconazole as the perpetrator underperformed: 12/27 DDI AUC(last) and 18/21 DDI C(max) ratios were within the success limits. MDPI 2023-02-17 /pmc/articles/PMC9965990/ /pubmed/36840001 http://dx.doi.org/10.3390/pharmaceutics15020679 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Marok, Fatima Zahra Wojtyniak, Jan-Georg Fuhr, Laura Maria Selzer, Dominik Schwab, Matthias Weiss, Johanna Haefeli, Walter Emil Lehr, Thorsten A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators |
title | A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators |
title_full | A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators |
title_fullStr | A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators |
title_full_unstemmed | A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators |
title_short | A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators |
title_sort | physiologically based pharmacokinetic model of ketoconazole and its metabolites as drug–drug interaction perpetrators |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965990/ https://www.ncbi.nlm.nih.gov/pubmed/36840001 http://dx.doi.org/10.3390/pharmaceutics15020679 |
work_keys_str_mv | AT marokfatimazahra aphysiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT wojtyniakjangeorg aphysiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT fuhrlauramaria aphysiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT selzerdominik aphysiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT schwabmatthias aphysiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT weissjohanna aphysiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT haefeliwalteremil aphysiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT lehrthorsten aphysiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT marokfatimazahra physiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT wojtyniakjangeorg physiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT fuhrlauramaria physiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT selzerdominik physiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT schwabmatthias physiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT weissjohanna physiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT haefeliwalteremil physiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators AT lehrthorsten physiologicallybasedpharmacokineticmodelofketoconazoleanditsmetabolitesasdrugdruginteractionperpetrators |